Sara Lubitz, MD
Endocrinology, Diabetes & Metabolism · New Brunswick, NJNPI 1568667855
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,730 of the $12,495 with a category attached, or 77.9%. Ascendis Pharma Endocrinology Inc accounts for 79.4% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $9,919, more than ten times the $76 reported in 2019.
Across 10 payments — averaging $1249.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$10K
- Neurocrine Biosciences, Inc.$3K
- Pfizer$76
Across 245 payments — averaging $607.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$61K
- Ascendis Pharma Endocrinology Inc$40K
- Amryt Pharma Holdings Ltd$22K
- Shire North American Group Inc$15K
- Chiasma, Inc.$10K
- Novartis$642
What the payments were for
- Consulting fees$2,50020%
- Speaking & faculty fees$9,73078%
- Travel & lodging$1011%
- Food & beverage$1641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 8 | $9,919 |
| Neurocrine Biosciences, Inc. | 1 | $2,500 |
| Pfizer | 1 | $76 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yorvipath$9,831
How this compares
$12,495 in reported general payments places this provider in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 22 | $41,230 |
| JardianceEmpagliflozin | 28 | $21,065 |
| MounjaroTirzepatide | 18 | $18,653 |
| SynthroidLevothyroxine Sodium | 133 | $12,145 |
| Levothyroxine Sodium | 321 | $3,857 |
| TirosintLevothyroxine Sodium | 15 | $3,100 |
| Cabergoline | 12 | $2,505 |
| Hydrocortisone | 44 | $1,842 |
| Armour ThyroidThyroid,pork | 19 | $1,247 |
| DottiEstradiol | 12 | $1,151 |
| Liothyronine Sodium | 13 | $714 |
| Calcitriol | 15 | $612 |
| LevoxylLevothyroxine Sodium | 16 | $553 |
| Repaglinide | 19 | $500 |
| Metformin Hcl | 26 | $324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerLevoxyl | $76 | $55316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in New Brunswick
- Joanne WaldstreicherNew Brunswick$441K
- Peter SteinNew Brunswick$40K
- Manu ChakravarthyNew Brunswick$16K
- Arthur SantoraNew Brunswick$15K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.